These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 13825787)

  • 1. [Clinical observations on children vaccinated against poliomyelitis (Salk vaccine)].
    FUTER DS; IAMPOL'SKAIA EI
    Sov Med; 1960 Jun; 24():9-16. PubMed ID: 13825787
    [No Abstract]   [Full Text] [Related]  

  • 2. [Formation and persistence of antibodies against poliomyelitis after vaccinations with Salk vaccine. A contribution to the value and limitations of Salk vaccinations].
    BUERGIN-WOLFF A; BERGER E
    Schweiz Med Wochenschr; 1960 Jun; 90():633-7. PubMed ID: 13805708
    [No Abstract]   [Full Text] [Related]  

  • 3. [Preparation and control of the Salk vaccine against poliomyelitis].
    DE SOMER P
    Belg Tijdschr Geneesk; 1956 Aug; 12(16):841-52. PubMed ID: 13355838
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the development of natural immunity to poliomyelitis in Louisiana. III. The serologic response to commercially produced "Salk vaccine" of children totally or partially susceptible to poliovirus infection.
    GELFAND HM; LeBLANC DR; FOX JP; POTASH L
    Am J Hyg; 1959 Nov; 70():303-11. PubMed ID: 13827181
    [No Abstract]   [Full Text] [Related]  

  • 5. [On neutralizing antibodies before and after vaccination against poliomyelitis with Salk vaccine].
    GILLERT KE; GRUETZNER L; HARTMANN H
    Zentralbl Bakteriol; 1960 Feb; 177():289-98. PubMed ID: 13850076
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the development of natural immunity to poliomyelitis in Louisiana. VI. The incidence of poliovirus infections during 1958 as an indication of the effect of Salk-type vaccine on virus dissemination.
    POTASH L; GELFAND HM; FOX JP
    Am J Hyg; 1960 May; 71():418-26. PubMed ID: 14434441
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccination against poliomyelitis in Poland with types 1 and 3 attenuated viruses of Koprowski. 1. Virological studies of the vaccine strains and serological studies of the vaccinated population.
    PRZESMYCKI F; DOBROWOLSKA H; MIRSKI B; WIOR H; STANCZYK R; ZALESKA H
    Bull World Health Organ; 1962; 26(6):733-43. PubMed ID: 14489069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present status of immunization against poliomyelitis (Salk vaccine versus living, attenuated virus).
    WEISS C
    J Albert Einstein Med Cent (Phila); 1956 Sep; 4(4):159-60. PubMed ID: 13357446
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of Salk vaccine in reducing nonparalytic poliomyelitis in a large urban epidemic.
    MARINE WM; CHIN TD; GRAVELLE CR; SOERGEL ME
    N Engl J Med; 1961 May; 264():903-7. PubMed ID: 13766783
    [No Abstract]   [Full Text] [Related]  

  • 10. Some statistical aspects of safety testing the Salk poliomyelitis vaccine.
    CORNFIELD J; HALPERIN M; MOORE F
    Public Health Rep (1896); 1956 Oct; 71(10):1045-56. PubMed ID: 13370807
    [No Abstract]   [Full Text] [Related]  

  • 11. Unpredictability of antibody response of infants to injections of Salk poliomyelitis vaccine.
    CRAMBLETT HG; FOMON SJ
    J Pediatr; 1961 Jun; 58():779-84. PubMed ID: 13696225
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis.
    MELNICK JL; BENYESH-MELNICK M; PENA R; YOW M
    JAMA; 1961 Apr; 175():1159-62. PubMed ID: 13769273
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous eruptions after use of Salk poliomyelitis vaccine.
    STROUD GM; BRODELL HL; LASCHEID WP; POTTS LW
    J Am Med Assoc; 1958 Jan; 166(3):251-3. PubMed ID: 13491335
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of Salk vaccine use in Delaware.
    HUDSON FI
    Del State Med J; 1956 Sep; 28(9):215-6. PubMed ID: 13365302
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody response to Salk vaccine in Norwegian school children.
    ULSTRUP JC; MEMMER R
    Arch Gesamte Virusforsch; 1959; 9():343-7. PubMed ID: 13840329
    [No Abstract]   [Full Text] [Related]  

  • 16. A study of the reasons for non-participation in the Salk vaccine program.
    HUGHES S
    Henry Ford Hosp Med Bull; 1959 Dec; 7():262-9. PubMed ID: 14403881
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of the effectiveness of Salk vaccine in Alberta with special reference to the outbreak of poliomyelitis in 1960.
    SMITH ES
    Can J Public Health; 1961 Nov; 52():467-73. PubMed ID: 13914212
    [No Abstract]   [Full Text] [Related]  

  • 18. [Report on the Salk vaccine].
    VIVELL
    Monatsschr Kinderheilkd (1902); 1956 Mar; 104(3):121-8. PubMed ID: 13321822
    [No Abstract]   [Full Text] [Related]  

  • 19. [Considerations for the implementation of the Salk vaccine].
    BUSTAMANTE W
    Rev Chil Pediatr; 1956 Mar; 27(3):123-7. PubMed ID: 13350716
    [No Abstract]   [Full Text] [Related]  

  • 20. Salk polio vaccine; comments concerning administration to allergic children.
    CRUMP J
    J Am Med Womens Assoc; 1956 Jul; 11(7):255. PubMed ID: 13345646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.